[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501163":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":25,"id":57,"slug":25,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":25,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calcitonin group","EXPERIMENTAL","patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.",[13],"Drug: Calcitonin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.",[19],"Drug: Placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Calcitonin",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Placebo",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Osama M Rehab, MD","CONTACT","00201095210806","osamarehab@med.tanta.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Tanta","Gharbia Governorate","31527","Egypt",{"type":43,"coordinates":44},"Point",[45,46],31.00192,30.78847,{"lat":46,"lon":45},[49,50],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Doha M Bakr, MD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Osama Rehab","lecturer of anesthesiology, surgical intensive care and pain medicine Tanta university","100501163",false,"NCT05805683","Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.\n\nExclusion Criteria:\n\n* Intake of anticonvulsants medications.\n* Evidence of neuropathic pain.\n* Evidence of previous allergic reaction to calcitonin.\n* Patients with renal, hepatic and cardiac dysfunction or neurological disorders .\n* brain damage or major trauma to extremities or abdomen.",true,"ALL","18 Years",{"count":67,"type":68},126,"ESTIMATED","INTERVENTIONAL",[71],"NA","This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury",[23,74,75],"Neuropathic Pain","Spinal Cord Injury",[23,77,78],"Neuropathic pain","Spinal cord injury","2026-05-11",{"date":81,"type":82},"2026-05-14","ACTUAL",{"date":84,"type":82},"2023-05-01",{"date":86,"type":68},"2028-05-01",{"name":5,"class":6},1]